Spearman’s correlation analysis further corroborated that the intestinal microbial alterations was closely linked to the expression of inflammatory cytokines, which might be attributed to the recovery of DNFB-induced AD-like skin lesions after treatment with DCP leading us to propose DCP as a promising novel microbiota-modulating agent for the treatment of AD. The gene discussed is ACE; the disease is Alzheimer disease.